Skip to main content
Top
Published in: Acta Diabetologica 3/2013

01-06-2013 | Original Article

Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes

Authors: Giovanni Sartore, Nino Cristiano Chilelli, Silvia Burlina, Annunziata Lapolla

Published in: Acta Diabetologica | Issue 3/2013

Login to get access

Abstract

There is a growing debate in the literature on whether glucose variability contributes, as well as high HbA1c levels and longstanding diabetes, to the onset and progression of diabetic retinopathy (DR) in patients with diabetes types 1 (DM1) and 2 (DM2). Few data, obtained only by self-monitoring of blood glucose, support this hypothesis. We used continuous glucose monitoring (CGM) to investigate the association between DR and glucose variability parameters (SD, CONGA 2, MAGE), acute hyperglycemia (HBGI) and chronic exposure to glucose (AG and AUC tot). We studied 68 patients from 19 to 69 years old, 35 with DM1 and 33 with DM2. The prevalence of retinopathy was 43 % in DM 1 patients and 39 % in DM 2 patients. The values of all indicators were obtained by CGM for 72 h. DR was diagnosed on direct or indirect ophthalmoscopic examination, after inducing mydriasis with tropicamide. HbA1c was measured at the baseline and 6 weeks after CGM to test the stability of the patients’ glycemic control. Univariate analysis showed a close association between DR and duration of diabetes (OR 1.11; 1.04–1.19), intensive insulin therapy (OR 5.6, CI 1.14–27.30), SD (OR 1.03; CI 1.01–1.06) and CONGA 2 (OR 1.02; CI 1.00–1.04)—both indicators of variability and HBGI (OR 1.1, CI 1.01–1.18)—a parameter reflecting acute hyperglycemia. There was no significant correlation with HbA1c (p = 0.070). Multivariate regression analysis showed that disease duration is the parameter most significantly correlating with DR (OR 1.05; 1.01–1.15). These results reinforce the evidence that longstanding disease is the factor most closely associated with DR. Our data also suggest, however, that glucose variability—regardless of HbA1c—may also have a role as a risk factor for DR, particularly in the case of acute fluctuations (as represented by CONGA 2 and SD) and acute hyperglycemia (as represented by HBGI).
Literature
1.
go back to reference Klein BE (2007) Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 14:179–183PubMedCrossRef Klein BE (2007) Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 14:179–183PubMedCrossRef
2.
go back to reference Klein R (2008) Epidemiology of Diabetic Retinopathy. In Duh E (ed.) Diabetic Retinopathy Klein R (2008) Epidemiology of Diabetic Retinopathy. In Duh E (ed.) Diabetic Retinopathy
4.
go back to reference DCCT research group (1993) The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 329:977–986CrossRef DCCT research group (1993) The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 329:977–986CrossRef
5.
go back to reference UK Prospective Diabetes Study group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837–853CrossRef UK Prospective Diabetes Study group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837–853CrossRef
6.
go back to reference Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN (2008) Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 57:995–1001PubMedCrossRef Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN (2008) Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 57:995–1001PubMedCrossRef
7.
8.
go back to reference Chang CM, Hsieh CJ, Huang JC, Huang IC (2012) Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes mellitus. Acta Diabetol. doi:10.1007/s00592-012-0398-x Chang CM, Hsieh CJ, Huang JC, Huang IC (2012) Acute and chronic fluctuations in blood glucose levels can increase oxidative stress in type 2 diabetes mellitus. Acta Diabetol. doi:10.​1007/​s00592-012-0398-x
9.
go back to reference Nalysnyk L, Hernandez-Medina M, Krishnarajah G (2010) Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 12:288–298PubMedCrossRef Nalysnyk L, Hernandez-Medina M, Krishnarajah G (2010) Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 12:288–298PubMedCrossRef
10.
go back to reference Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH (2010) Glucose variability: does it matter? Endocr Rev 31:171–182PubMedCrossRef Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH (2010) Glucose variability: does it matter? Endocr Rev 31:171–182PubMedCrossRef
11.
go back to reference De Block C, Manuel-y-Keenoy B, Van Gaal L (2008) A review of current evidence with continuous glucose monitoring in patients with diabetes. J Diabetes Sci Technol 2:718–727PubMed De Block C, Manuel-y-Keenoy B, Van Gaal L (2008) A review of current evidence with continuous glucose monitoring in patients with diabetes. J Diabetes Sci Technol 2:718–727PubMed
12.
go back to reference Hoekstra JB, Nathan DMJ, Borg R, Zheng H, Schoenfeld D, Heine RJ for the A1c-Derived Average Glucose (ADAG) Study Group (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31:1473–1478CrossRef Hoekstra JB, Nathan DMJ, Borg R, Zheng H, Schoenfeld D, Heine RJ for the A1c-Derived Average Glucose (ADAG) Study Group (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31:1473–1478CrossRef
13.
go back to reference Sartore G, Chilelli NC, Burlina S, Stefano PD, Piarulli F, Fedele D, Mosca A, Lapolla A (2012) The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM). Acta Diabetol. doi:10.1007/s00592-012-0391-4 Sartore G, Chilelli NC, Burlina S, Stefano PD, Piarulli F, Fedele D, Mosca A, Lapolla A (2012) The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM). Acta Diabetol. doi:10.​1007/​s00592-012-0391-4
14.
go back to reference Klonoff DC (2005) Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 28:1231–1239PubMedCrossRef Klonoff DC (2005) Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 28:1231–1239PubMedCrossRef
15.
go back to reference Ceriello A, Ihnat MA (2010) ‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 27:862–867PubMedCrossRef Ceriello A, Ihnat MA (2010) ‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 27:862–867PubMedCrossRef
16.
go back to reference Rodbard D (2009) New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 11:551–565PubMedCrossRef Rodbard D (2009) New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 11:551–565PubMedCrossRef
17.
go back to reference Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644–656PubMed Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644–656PubMed
18.
go back to reference McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ (2005) A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 7:253–263PubMedCrossRef McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ (2005) A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 7:253–263PubMedCrossRef
19.
go back to reference Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W (2006) Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 29:2433–2438PubMedCrossRef Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W (2006) Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 29:2433–2438PubMedCrossRef
20.
go back to reference Early Treatment Diabetic Retinopathy Study Research Group (1991) Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Arlie house classification. ETDRS report number 10. Ophtalmology 98:786–806 Early Treatment Diabetic Retinopathy Study Research Group (1991) Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Arlie house classification. ETDRS report number 10. Ophtalmology 98:786–806
21.
go back to reference Wilkinson CP, Ferris FL 3rd, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682PubMedCrossRef Wilkinson CP, Ferris FL 3rd, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682PubMedCrossRef
22.
go back to reference Hammes HP, Kerner W, Hofer S, Kordonouri O, Raile K, Holl RW on behalf of the DPV–Wiss Study Group (2011) Diabetic retinopathy in type 1 diabetes—a contemporary analysis of 8,784 patients. Diabetologia 54:1977–1984PubMedCrossRef Hammes HP, Kerner W, Hofer S, Kordonouri O, Raile K, Holl RW on behalf of the DPV–Wiss Study Group (2011) Diabetic retinopathy in type 1 diabetes—a contemporary analysis of 8,784 patients. Diabetologia 54:1977–1984PubMedCrossRef
23.
go back to reference Kempen JH, O’ Colmain BJ, Leske MC et al (2004) The prevalence of diabetic retinopathy among adults in the United States. Arch Ophtalmol 122:552–563CrossRef Kempen JH, O’ Colmain BJ, Leske MC et al (2004) The prevalence of diabetic retinopathy among adults in the United States. Arch Ophtalmol 122:552–563CrossRef
24.
go back to reference Bolli GB, Andreoli AM, Lucidi P (2011) Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 13:S43–S52PubMedCrossRef Bolli GB, Andreoli AM, Lucidi P (2011) Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 13:S43–S52PubMedCrossRef
25.
go back to reference Stolar M (2010) Glycemic control and complications in type 2 diabetes mellitus. The American Journal of Medicine 123:S3–S11PubMedCrossRef Stolar M (2010) Glycemic control and complications in type 2 diabetes mellitus. The American Journal of Medicine 123:S3–S11PubMedCrossRef
26.
go back to reference Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freise EJ et al (2009) Glycemic variability correlates strongly with postprandial β-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 32:1058–1062PubMedCrossRef Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freise EJ et al (2009) Glycemic variability correlates strongly with postprandial β-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 32:1058–1062PubMedCrossRef
27.
go back to reference Lam CSY, Benzie IFF, Choi SW, Chan LYL, Yeung VTF, Woo GC (2011) Relationships among diabetic retinopathy, antioxidants, and glycemic control. Optom Vis Sci 88:251–256PubMedCrossRef Lam CSY, Benzie IFF, Choi SW, Chan LYL, Yeung VTF, Woo GC (2011) Relationships among diabetic retinopathy, antioxidants, and glycemic control. Optom Vis Sci 88:251–256PubMedCrossRef
28.
go back to reference Monnier L, Colette C, Owens D (2012) The glycemic triumvirate and diabetic complications: is the whole greater than the sum of its component parts? Diabetes Res Clin Pract 95:303–311PubMedCrossRef Monnier L, Colette C, Owens D (2012) The glycemic triumvirate and diabetic complications: is the whole greater than the sum of its component parts? Diabetes Res Clin Pract 95:303–311PubMedCrossRef
29.
go back to reference Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903PubMedCrossRef
30.
go back to reference Zoppini G, Verlato G, Targer G et al (2008) Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? NMCD 19:334–339PubMed Zoppini G, Verlato G, Targer G et al (2008) Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? NMCD 19:334–339PubMed
31.
go back to reference Takao T, Ide T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y (2011) The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients. Diabetes Res Clin Pract 91:e40–e42PubMedCrossRef Takao T, Ide T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y (2011) The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients. Diabetes Res Clin Pract 91:e40–e42PubMedCrossRef
32.
go back to reference Patton SR, Midyett LK, Dolan LM, Powers SW (2011) A comparison of average daily risk range scores for young children with type 1 diabetes mellitus using continuous monitoring and self-monitoring data. Diabetes Technol Ther 14:239–243PubMedCrossRef Patton SR, Midyett LK, Dolan LM, Powers SW (2011) A comparison of average daily risk range scores for young children with type 1 diabetes mellitus using continuous monitoring and self-monitoring data. Diabetes Technol Ther 14:239–243PubMedCrossRef
33.
go back to reference Vazeou A (2011) Continuous blood glucose monitoring in diabetes treatment. Diabetes Res Clin Pract 93:S125–S130PubMedCrossRef Vazeou A (2011) Continuous blood glucose monitoring in diabetes treatment. Diabetes Res Clin Pract 93:S125–S130PubMedCrossRef
34.
go back to reference Monnier L, Colette C, Owens DR (2008) Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2:1094–1100PubMed Monnier L, Colette C, Owens DR (2008) Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2:1094–1100PubMed
35.
go back to reference Ceriello A, Ihnat MA, Thorpe JE (2009) Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 94:410–415PubMedCrossRef Ceriello A, Ihnat MA, Thorpe JE (2009) Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 94:410–415PubMedCrossRef
Metadata
Title
Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes
Authors
Giovanni Sartore
Nino Cristiano Chilelli
Silvia Burlina
Annunziata Lapolla
Publication date
01-06-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-013-0459-9

Other articles of this Issue 3/2013

Acta Diabetologica 3/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.